Thalassemia major 1995: older patients, new therapies.
There have been many advances in supportive treatment used for beta-thalassemia major. Survival has increased substantially, and an increasing number of patients reach adolescence and adulthood. These older patients present new clinical challenges. Complications of transfusion, most commonly hepatitis C, are still a cause of mortality and morbidity. The achievement of optimal growth and development, including fertility, is an important goal of conservative management. Long-term survival has also been achieved with bone marrow transplantation. Assessment of growth, development and iron balance in the years after transplantation reveals residual problems requiring treatment despite cure of thalassemia. New therapies of beta-thalassemia are still being developed, both supportive and curative in nature. Supportive care improvements include oral chelation and methods to increase HbF production. Advances in curative modalities include use of new sources of stem cells, such as cord blood and fetal liver. In the future, gene therapy may allow for cure of the older patient without the mortality and morbidity of allogenic transplantation. Treatment of thalassemia major requires consideration of the available therapeutic options for each patient, and the risk/benefit ratio of a supportive versus curative approach.
Rund
D
D
Hematology Department, Hadassah University Hospital, Ein Kerem, Jerusalem, Israel.
Rachmilewitz
E
E
D000367:Age Factors; D000818:Animals; D016026:Bone Marrow Transplantation; D004700:Endocrine System Diseases / Q000209:etiology / Q000628:therapy; D005260:Female; D005544:Forecasting; D006509:Hepatitis B / Q000209:etiology; D006526:Hepatitis C / Q000209:etiology; D006801:Humans; D008297:Male; D011247:Pregnancy; D065227:Transfusion Reaction; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000150:complications / Q000601:surgery / Q000628:therapy*